Premium
Interpretation of interleukin‐2 receptor alpha positive cells during induction chemotherapy for adult acute myelogenous leukaemia patients
Author(s) -
Min WooSung,
Kim HeeJe,
Choi Young,
Jeong HyeYoung,
Kim ChunChoo
Publication year - 2007
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.807
Subject(s) - il 2 receptor , medicine , chemotherapy , receptor , interleukin 2 , induction chemotherapy , alpha (finance) , gastroenterology , immunology , t cell , surgery , immune system , construct validity , patient satisfaction
To correlate clinical outcomes with the expression of interleukin‐2 receptor alpha (CD25) positive cells during induction chemotherapy (IC) in adult patients with acute myeloid leukaemia (AML), we investigated the prognostic importance of subsets of peripheral blood (PB) CD45+CD25+ cells. Seventy‐five patients with newly diagnosed AML received the same initial IC; and serial PB samples were taken. The gated CD45/CD25 cell populations were used to compare the intensity of immunophenotypic signals based on the treatment timeline. Patients who responded poorly to IC demonstrated exceptionally higher levels of PB CD45+CD25+ cells by percentage ( p = 0.003) or by absolute count ( p = 0.046) on the seventh day (D + 7) of initial IC. In addition, patients in complete remission (CR) ( n = 61) demonstrated relatively lower levels of steady PB CD45+CD25+ after standard IC. These results suggest that the expression of CD25 can be used to predict the response to IC during an early period of treatment. Copyright © 2007 John Wiley & Sons, Ltd.